Notes on Progress in the New Zealand Ibogaine Study - Geoff Noller

Ibogaine research in New Zealand is evaluated through an observational study examining its efficacy in treating individuals struggling with opioid dependence. Despite the limited initial adoption, legislative changes in 2010 allowed for medically supervised usage, facilitating a structured clinical observation. The study tracks participants over a 12-month period, utilizing tools like the Addiction Severity Index and the Beck Depression Inventory to measure outcomes related to substance use, cravings, and well-being. - Data from the participant pool highlights both the therapeutic potential of ibogaine and the intricacies of managing patient care, particularly regarding polydrug use and the challenges of patient retention. The findings underscore the critical importance of a supportive, medically informed approach in managing the post-treatment phase for those seeking sustainable recovery.